Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia (Q33377623)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia |
scientific article |
Statements
1 reference
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia (English)
1 reference
Elisabetta Abruzzese
1 reference
Hagop Kantarjian
1 reference
Jorge Cortes
1 reference
Giovanni Martinelli
1 reference
Michele Baccarani
1 reference
Francis Giles
1 reference
Norbert Gattermann
1 reference
Kazimierz Kuliczkowski
1 reference
Jane F Apperley
1 reference
Jerald P Radich
1 reference
Philipp le Coutre
1 reference
Francois-Xavier Mahon
1 reference
Yaping Shou
1 reference
Dong-Wook Kim
1 reference
Stephen G O'Brien
1 reference
Marco Gobbi
1 reference
Yok-Lam Kwong
1 reference
Timothy Hughes
1 reference
Ming Zheng
1 reference
29 November 2007
1 reference
Identifiers
1 reference